Hsiaowei Deng

1.4k total citations · 1 hit paper
11 papers, 1.0k citations indexed

About

Hsiaowei Deng is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Hsiaowei Deng has authored 11 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Surgery, 6 papers in Cardiology and Cardiovascular Medicine and 3 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Hsiaowei Deng's work include Antiplatelet Therapy and Cardiovascular Diseases (3 papers), Diabetes Treatment and Management (3 papers) and Atrial Fibrillation Management and Outcomes (3 papers). Hsiaowei Deng is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (3 papers), Diabetes Treatment and Management (3 papers) and Atrial Fibrillation Management and Outcomes (3 papers). Hsiaowei Deng collaborates with scholars based in United States, United Kingdom and Germany. Hsiaowei Deng's co-authors include Kenneth W. Mahaffey, Bruce Neal, Vlado Perkovic, David R. Matthews, Greg Fulcher, Dick de Zeeuw, Ngozi Erondu, Wayne Shaw, Terrance D. Barrett and Michele A. Weidner‐Wells and has published in prestigious journals such as Circulation, The Journal of Clinical Endocrinology & Metabolism and European Heart Journal.

In The Last Decade

Hsiaowei Deng

10 papers receiving 993 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

2018 468 citations Vlado Perkovic, Dick de Zeeuw et al. The Lancet Diabetes & Endocrinology profile →

Peers

Countries citing papers authored by Hsiaowei Deng

Since Specialization

Citations

This map shows the geographic impact of Hsiaowei Deng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hsiaowei Deng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hsiaowei Deng more than expected).

Fields of papers citing papers by Hsiaowei Deng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hsiaowei Deng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hsiaowei Deng. The network helps show where Hsiaowei Deng may publish in the future.

Co-authorship network of co-authors of Hsiaowei Deng

This figure shows the co-authorship network connecting the top 25 collaborators of Hsiaowei Deng. A scholar is included among the top collaborators of Hsiaowei Deng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hsiaowei Deng. Hsiaowei Deng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS) 2025 ·American Heart Journal ·C. Michael Gibson, Maria Cecilia Bahit, Roxana Mehran, Shamir R Mehta, (unknown), Shinya Goto, Jeffrey I. Weitz, Jay Horrow, (unknown), Robert A. Harrington, Kenneth W. Mahaffey, (unknown), Karen S. Pieper, S. Claiborne Johnston, Graeme J. Hankey, Alexei N. Plotnikov, Danshi Li, Hsiaowei Deng, Philippe Gabríel Steg	4
2	Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD 2025 ·Journal of the American Heart Association ·(unknown), Michael Szarek, E. Sebastian Debus, Mark R. Nehler, Sonia S. Anand, Manesh R. Patel, Ákos F. Pap, Hsiaowei Deng, (unknown), Lloyd Haskell, Eva Muehlhofer, Scott D. Berkowitz, Rupert Bauersachs, Marc P. Bonaca	0
3	Quantitative Benefit–Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial 2024 ·Journal of the American Heart Association ·Žhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert Bauersachs, Scott D. Berkowitz, Lloyd Haskell, Elliot S. Barnathan, Marc P. Bonaca	3
4	Evaluation of the benefit of rivaroxaban on VOYAGER PAD primary composite of limb, heart and brain outcomes using the global rank and win ratio methods 2022 ·European Heart Journal ·Marc P. Bonaca, E. Sebastian Debus, Mark R. Nehler, (unknown), Manesh R. Patel, Ákos F. Pap, Hsiaowei Deng, (unknown), Michael Szarek, Lloyd Haskell, Eva Muehlhofer, Scott D. Berkowitz, Rupert Bauersachs	1
5	Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial 2020 ·JACC Heart Failure ·Jonathan W. Cunningham, João Pedro Ferreira, Hsiaowei Deng, Stefan D. Anker, William M. Byra, John G.F. Cleland, Mihai Gheorghiade, Carolyn S.P. Lam, (unknown), Mandeep R. Mehra, James D. Neaton, Theodore E. Spiro, Dirk J. van Veldhuisen, Barry Greenberg, Faı̈ez Zannad	10
6	A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial 2019 ·European Heart Journal ·Mandeep R. Mehra, Muthiah Vaduganathan, Min Fu, João Pedro Ferreira, Stefan D. Anker, John G.F. Cleland, Carolyn S.P. Lam, Dirk J. van Veldhuisen, William M. Byra, Theodore E. Spiro, Hsiaowei Deng, Faı̈ez Zannad, Barry Greenberg	61
7	Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm 2019 ·JAMA Cardiology ·Barry Greenberg, James D. Neaton, Stefan D. Anker, William M. Byra, John G.F. Cleland, Hsiaowei Deng, Min Fu, (unknown), Carolyn S.P. Lam, Mandeep R. Mehra, Christopher C. Nessel, Theodore E. Spiro, Dirk J. van Veldhuisen, (unknown), Faı̈ez Zannad	44
8	Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials breakdown → 2018 ·The Lancet Diabetes & Endocrinology ·Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D. Barrett, Michele A. Weidner‐Wells, Hsiaowei Deng, David R. Matthews, Bruce Neal	468
9	Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function 2018 ·Circulation ·Brendon L. Neuen, Toshiaki Ohkuma, Bruce Neal, David R. Matthews, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Mehul Desai, Qiang Li, Hsiaowei Deng, Norm Rosenthal, Meg Jardine, George L. Bakris, Vlado Perkovic	188
10	Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal ( CANVAS‐R ): A randomized, placebo‐controlled trial 2017 ·Diabetes Obesity and Metabolism ·Bruce Neal, Vlado Perkovic, David R. Matthews, Kenneth W. Mahaffey, Greg Fulcher, Gary Meininger, Ngozi Erondu, Mehul Desai, Wayne Shaw, Frank Vercruysse, Jacqueline Yee, Hsiaowei Deng, Dick de Zeeuw, (unknown)	122
11	123I-Meta-Iodobenzylguanidine Scintigraphy for the Detection of Neuroblastoma and Pheochromocytoma: Results of a Meta-Analysis 2010 ·The Journal of Clinical Endocrinology & Metabolism ·Arnold Jacobson, Hsiaowei Deng, (unknown), (unknown), Richard R. Black	103

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact